Researchers in the Cancer Immunology, Inflammation and Tolerance program use a range
of techniques to study how the immune system influences tumorigenesis and cancer therapy.
The immune system can inhibit or promote tumor progression in local tissues where
pre-malignancies form. Major program themes are to elucidate
How pre-malignancies create and sustain local immunologic tolerance necessary for
tumor formation
How to destroy local tolerance that protects tumors from natural and vaccine-induced
anti-tumor immunity.
The scientific rationale for this dual approach is that pre-malignant cells create
and sustain tolerance during tumor progression, while breaking tumor-associated tolerance
is necessary for successful anti-tumor treatment. Hence, program goals are to elucidate
molecular and cellular pathways at sites of inflammation that promote or break immune
tolerance using pre-clinical mouse models of tumor progression and autoimmune syndromes,
and developing novel immunotherapies to treat these syndromes more effectively by
targeting tolerance pathways. To this end, program faculty also engage in promoting
pre-clinical research and early-phase clinical trials of novel vaccine adjuvants to
improve cancer immunotherapy, in some cases with corporate partners.
To pursue these focused research themes and scientific goals, program faculty employ
many state-of-the-art techniques, facilities, and unique resources, including flow
cytometric sorting and analysis, a range of molecular imaging techniques, genomic
analysis, and genetically modified mouse strains. Future program development will
build on existing CIT program strengths by recruiting new investigators with expertise
in inflammation, immunological, and metabolic research to complement current research
focused on regulation of adaptive immunity.
I was trained as a physician, but has been fascinated by how our body’s immune system
has been so effective to control not only microbial infections, but also cancer cells.
We had studied the basic mechanism of how cancer vaccines activated immune responses
and applied the vaccine design technologies into developing liver cancer vaccines.
Over the last decade, research in my lab has been focusing on identifying novel T
cell receptors (TCR) and on developing new chimeric antigen receptors (CAR) for liver
cancer immunotherapy. We are fortunate that our research has been continuously funded
by NCI/NIH grants. Our goal is to engineer immune T cells to become potent and targeted
fighters to eliminate cancer cells and cure cancer patients.
The grant awarded for Chadli’s research focuses on a specific protein, UNC45A, that can be used as a promising novel immunotherapeutic target in treating triple-negative breast cancer (TNBC).
A study conducted by a team of researchers from the Dental College of Georgia at Augusta University tested inhalant CBD in the treatment of lung cancer and whether it could inhibit tumors from growing or spreading.